close

Agreements

1 2 3 233
Number of results: 4647

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2018-08-16 BioNTech (Germany) Pfizer (USA - NY) mRNA?based flu vaccines influenza (flu) research - development - R&D Infectious diseases Development agreement
2018-08-07 Infinity Pharmaceuticals (USA - MA) nomination Cancer - Oncology Nomination
2018-08-06 Boehringer Ingelheim (Germany) Oxford Biomedica (UK) UK Cystic Fibrosis Gene Therapy Consortium (UK) Imperial Innovations (UK) replication-deficient lentiviral vector in an inhaled formulation, to introduce a healthy copy of the CFTR gene into the cells of the lung cystic fibrosis collaboration Rare diseases - Genetic diseases - Respiratory diseases Collaboration agreement
2018-08-06 Bluebird bio (USA - MA) Regeneron Pharmaceuticals (USA - NY) immune cell therapies research - development - R&D - commercialisation Cancer - Oncology Collaboration agreement
2018-08-03 HTG Molecular Diagnostics (USA - AZ) Oncologie (USA - MA) biomarkers associated with Oncologie’s Immuno-oncology pipeline development Development agreement
2018-08-02 Atlantic Healthcare (UK) US president and CEO nomination Inflammatory diseases - Gastrointestinal diseases Nomination
2018-08-02 Orchard Therapeutics (UK) member of the board of directors nomination Rare diseases - Genetic diseases Nomination
2018-08-01 BioNTech (Germany) SiO2 Medical Products (“SMP”) (USA - Ala) packaging and application devices for mRNA therapeutics collaboration Technology - Services Collaboration agreement
2018-07-25 GSK (UK) 23andme (USA - CA) collaboration - research - development Collaboration agreement
2018-07-10 MedImmune (USA - global biologics arm of AstraZeneca (UK) 4D Molecular Therapeutics (USA - CA) AAV vectors chronic lung disease development - commercialisation Lung diseases - Respiratory diseases Development agreement
2018-07-10 BioNTech (Germany) Genevant Sciences (USA - MA) five mRNA therapeutic programs for rare diseases with high unmet medical need Rare diseases development - commercialisation Rare diseases - Genetic diseases Development agreement
2018-07-09 Orchard Therapeutics (UK) member of the board of directors nomination Rare diseases - Genetic diseases Nomination
2018-07-09 Benitec Biopharma (Australia) Axovant (UK)
  • BB-301, now named AXO-AAV-OPMD (genetically modified adeno-associated viral vector serotype 9 expressing shRNA as well as a codon-optimised shRNA-insensitive wildtype PABPN1) and five additional gene therapy products in neurological disorders
oculopharyngeal muscular dystrophy (OPMD) amyotrophic lateral sclerosis (ALS) frontotemporal dementia (FTD) licensing - research - development Rare diseases - Genetic diseases - Neurological diseases Licensing agreement
2018-06-29 Orchard Therapeutics (UK) chairman of the board of directors nomination Rare diseases - Genetic diseases Nomination
2018-06-27 Avrobio (USA - MA) member of the board of directors nomination Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases Nomination
2018-06-11 RegenXBio (USA - MD) Avexis (USA - MA) products to treat Spinal Muscular Atrophy (SMA) using NAV rAAV9 vectors spinal muscular atrophy licensing Rare diseases - Genetic diseases - Neuromuscular diseases Milestone
2018-06-08 Amicus Therapeutics (USA - NJ) member of the board of directors nomination Rare diseases - Genetic diseases Nomination
2018-06-07 Orchard Therapeutics (UK) member of the board of directors nomination Rare diseases - Genetic diseases Nomination
2018-05-29 BioNTech (Germany) nomination Cancer - Oncology - Infectious diseases Nomination
2018-05-15 Horama (France) chairman of the board of directors nomination Rare diseases - Genetic diseases - Ophtalmological diseases Nomination